Polyrizon Stock
Polyrizon Ltd.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- CEO
- Tomer Izraeli
- Employees
- 6
- Market cap
- $11 M
- IPO
- 29/10/2024
Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current…
Polyrizon stock: price history
1D
-0.1%
1W
+11.2%
1M
-6.1%
6M
-12.4%
YTD
+17.8%
1Y
+55.8%
2Y
–
5Y
–
10Y
–
Ask the agents about Polyrizon
Polyrizon stock metrics
P/E
-2.2
P/B
0.74
EV/EBITDA
-0.23
RETURN ON EQUITY
-5.8%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
93.9%
FLOAT SHARES
1,051,470
AVG. DAILY VOLUME (30D)
41,765
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Polyrizon stock
What does Polyrizon do?
Polyrizon Ltd. is a company in the Healthcare sector, Biotechnology industry, headquartered in Israel.
The CEO is Tomer Izraeli, the company employs around 6 people.
The IPO was on 29/10/2024; the stock trades on NASDAQ under the ticker PLRZ.
Does Polyrizon pay a dividend?
No, Polyrizon currently does not pay a dividend.
Which stocks are comparable to Polyrizon?
Comparable stocks include Alpha Tau Medical, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines and Incyte.
How can I get Polyrizon stock analyzed?
Clicking "Analyze stock" lets five strategies assess Polyrizon against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.